Potential approval delayed for Sarepta's Duchenne drug; shares plunge

Duchenne muscular dystrophy patients and their families were delivered a heartbreaking setback this morning when Sarepta Therapeutics, which is developing a treatment to slow the progression of the disease, said it won't file for approval for several months later than hoped...